End-of-study OS and PFS in patients with relapsed or refractory systemic ALCL treated with brentuximab vedotin. OS and PFS per investigator assessment were analyzed using Kaplan-Meier methodology. Median observation time was 6 years from the start of treatment. Patients were observed for a median of 5 years after the end of treatment. (A) OS for all patients. (B) OS by best response. (C) PFS for all patients. (D) PFS by best response.